Rabeprazole Sodium interactions
Checked as Rabeprazole in this data source.
Full monograph for Rabeprazole SodiumCheck it against another medicine
Medicines
564 documented
| Medicine | Severity | Mechanism | Effect | Sources |
|---|---|---|---|---|
| Acalabrutinib | Major | Absorption | Coadministration with proton pump inhibitors may significantly decrease the oral bioavailability of acalabrutinib and reduce its concentrations in plasma. The… | 2 sources — open the full entry |
| Clopidogrel + Aspirin | Major | Absorption · Metabolism | Coadministration with proton pump inhibitors (PPIs) may reduce the cardioprotective effects of clopidogrel. The proposed mechanism is PPI inhibition of the…2 documented mechanisms | 29 sources — open the full entry |
| Clopidogrel Bisulphate | Major | Metabolism | Coadministration with proton pump inhibitors (PPIs) may reduce the cardioprotective effects of clopidogrel. The proposed mechanism is PPI inhibition of the… | 24 sources — open the full entry |
| Dacomitinib | Major | Absorption | Coadministration with proton pump inhibitors (PPIs) may decrease the plasma concentrations of dacomitinib. The proposed mechanism is a pH-dependent reduction… | 2 sources — open the full entry |
| Dasatinib | Major | Absorption | Nonclinical data indicate that the solubility of dasatinib is pH-dependent. Therefore, long-term suppression of gastric acid secretion by H2-receptor… | 4 sources — open the full entry |
| Erlotinib | Major | Absorption | Concurrent administration of agents that increase gastric pH such as proton pump inhibitors may decrease the oral bioavailability of erlotinib and reduce its… | 6 sources — open the full entry |
| Methotrexate | Major | Excretion | Coadministration with proton pump inhibitors (PPIs) may increase the serum concentrations of methotrexate (MTX) and its potentially active 7-hydroxy… | 7 sources — open the full entry |
| Nelfinavir | Major | Absorption | Concurrent use of proton pump inhibitors may decrease the oral bioavailability of nelfinavir and reduce its concentrations in plasma. Nelfinavir solubility may… | 2 sources — open the full entry |
| Neratinib Maleate | Major | Absorption | Coadministration with proton pump inhibitors or H2-receptor antagonists may significantly decrease the oral bioavailability of neratinib. The solubility of… | 5 sources — open the full entry |
| Pazopanib Hydrochloride | Major | Absorption | Coadministration with proton pump inhibitors or H2-receptor antagonists may significantly decrease the oral bioavailability of pazopanib and reduce its… | 7 sources — open the full entry |
| Selpercatinib | Major | Absorption | Coadministration with drugs that increase gastric pH may significantly decrease the oral bioavailability of selpercatinib and reduce its concentrations in… | 2 sources — open the full entry |
| Sofosbuvir + Velpatasvir | Major | Absorption | Coadministration of velpatasvir with proton pump inhibitors may reduce its gastrointestinal absorption. Velpatasvir exhibits pH-dependent solubility, with…2 documented mechanisms | 4 sources — open the full entry |
| Sotorasib | Major | Absorption | Coadministration with drugs that increase gastric pH may significantly decrease the oral bioavailability of sotorasib and reduce its concentrations in plasma. | 2 sources — open the full entry |
| Abametapir | Moderate | Metabolism | Based on in vitro inhibition data, a single topical application of abametapir lotion may increase plasma concentrations of drugs that are substrates of CYP450… | 1 sources — open the full entry |
| Amikacin | Moderate | Synergy | Chronic use of proton pump inhibitors (PPIs) may induce hypomagnesemia, and the risk may be increased during concomitant use of diuretics or other agents that… | 3 sources — open the full entry |
| Amphotericin B | Moderate | Synergy | Chronic use of proton pump inhibitors (PPIs) may induce hypomagnesemia, and the risk may be increased during concomitant use of diuretics or other agents that… | 3 sources — open the full entry |
| Apalutamide | Moderate | Absorption · Metabolism | Coadministration with apalutamide may decrease the plasma concentrations and therapeutic effects of drugs that are substrates of CYP450 3A4, 2C9, 2C19, breast… | 5 sources — open the full entry |
| Aprepitant | Moderate | Metabolism | Coadministration with aprepitant or its prodrug, fosaprepitant, may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4… | 2 sources — open the full entry |
| Armodafinil | Moderate | Metabolism | Coadministration with modafinil (the racemate) or armodafinil (the R-enantiomer) may increase the plasma concentrations of drugs that are primarily metabolized… | 9 sources — open the full entry |
| Atenolol + Chlorthalidone | Moderate | Synergy · Unknown | Chronic use of proton pump inhibitors (PPIs) may induce hypomagnesemia, and the risk may be increased during concomitant use of diuretics or other agents that…2 documented mechanisms | 3 sources — open the full entry |
| Azilsartan Medoxomil + Chlorthalidone | Moderate | Synergy | Chronic use of proton pump inhibitors (PPIs) may induce hypomagnesemia, and the risk may be increased during concomitant use of diuretics or other agents that… | 3 sources — open the full entry |
| Betamethasone + Clotrimazole + Gentamicin | Moderate | Synergy · Unknown | Chronic use of proton pump inhibitors (PPIs) may induce hypomagnesemia, and the risk may be increased during concomitant use of diuretics or other agents that…2 documented mechanisms | 3 sources — open the full entry |
| Betamethasone + Neomycin Sulphate (Ophthalmic) | Moderate | Synergy | Chronic use of proton pump inhibitors (PPIs) may induce hypomagnesemia, and the risk may be increased during concomitant use of diuretics or other agents that… | 3 sources — open the full entry |
| Bisoprolol Fumarate + Hydrochlorothiazide | Moderate | Synergy · Unknown | Chronic use of proton pump inhibitors (PPIs) may induce hypomagnesemia, and the risk may be increased during concomitant use of diuretics or other agents that…2 documented mechanisms | 3 sources — open the full entry |
| Brigatinib | Moderate | Metabolism | Coadministration with brigatinib may decrease the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. Brigatinib has been shown in… | 6 sources — open the full entry |
| Bumetanide | Moderate | Synergy | Chronic use of proton pump inhibitors (PPIs) may induce hypomagnesemia, and the risk may be increased during concomitant use of diuretics or other agents that… | 3 sources — open the full entry |
| Candesartan Cilexetil + Hydrochlorothiazide | Moderate | Synergy | Chronic use of proton pump inhibitors (PPIs) may induce hypomagnesemia, and the risk may be increased during concomitant use of diuretics or other agents that… | 3 sources — open the full entry |
| Carbonyl Iron + Folic Acid | Moderate | Absorption · Unknown | The profound hypochlorhydria induced by proton pump inhibitors (PPIs) may impair the gastrointestinal absorption of nonheme iron, a process that is dependent…2 documented mechanisms | 12 sources — open the full entry |
| Carbonyl Iron + Folic Acid + Zinc Sulfate | Moderate | Absorption · Unknown | The profound hypochlorhydria induced by proton pump inhibitors (PPIs) may impair the gastrointestinal absorption of nonheme iron, a process that is dependent…2 documented mechanisms | 12 sources — open the full entry |
| Carbonyl Iron + Folic Acid + Zinc Sulfate + Vitamin B Complex + Vitamin C | Moderate | Absorption · Unknown | The profound hypochlorhydria induced by proton pump inhibitors (PPIs) may impair the gastrointestinal absorption of nonheme iron, a process that is dependent…2 documented mechanisms | 12 sources — open the full entry |
| Carboplatin | Moderate | Synergy | Chronic use of proton pump inhibitors (PPIs) may induce hypomagnesemia, and the risk may be increased during concomitant use of diuretics or other agents that… | 3 sources — open the full entry |
| Cefditoren | Moderate | Absorption | Coadministration with H2-receptor antagonists or other agents that reduce stomach acid (e.g., proton pump inhibitors) may decrease the oral absorption and… | 2 sources — open the full entry |
| Cefpodoxime Proxetil | Moderate | Absorption | The coadministration with H2-receptor antagonists, proton pump inhibitors, or other agents that can increase gastric pH may reduce the oral bioavailability of… | 4 sources — open the full entry |
| Cefpodoxime Proxetil + Clavulanic Acid | Moderate | Absorption | The coadministration with H2-receptor antagonists, proton pump inhibitors, or other agents that can increase gastric pH may reduce the oral bioavailability of… | 4 sources — open the full entry |
| Cefuroxime Axetil | Moderate | Absorption | The coadministration with H2-receptor antagonists, proton pump inhibitors, or other agents that can increase gastric pH may reduce the oral bioavailability of… | 4 sources — open the full entry |
| Cefuroxime Axetil + Clavulanic Acid | Moderate | Absorption | The coadministration with H2-receptor antagonists, proton pump inhibitors, or other agents that can increase gastric pH may reduce the oral bioavailability of… | 4 sources — open the full entry |
| Ceritinib | Moderate | Absorption | Drugs that alter the pH of the upper gastrointestinal tract may affect the solubility of ceritinib and reduce its bioavailability. The interaction has not been… | 2 sources — open the full entry |
| Cetuximab | Moderate | Synergy | Chronic use of proton pump inhibitors (PPIs) may induce hypomagnesemia, and the risk may be increased during concomitant use of diuretics or other agents that… | 3 sources — open the full entry |
| Chlorthalidone | Moderate | Synergy | Chronic use of proton pump inhibitors (PPIs) may induce hypomagnesemia, and the risk may be increased during concomitant use of diuretics or other agents that… | 3 sources — open the full entry |
| Cinchocaine + Hydrocortisone + Framycetin + Esculin | Moderate | Synergy · Unknown | Chronic use of proton pump inhibitors (PPIs) may induce hypomagnesemia, and the risk may be increased during concomitant use of diuretics or other agents that…2 documented mechanisms | 3 sources — open the full entry |
| Cinchocaine + Hydrocortisone + Neomycin + Esculin | Moderate | Synergy · Unknown | Chronic use of proton pump inhibitors (PPIs) may induce hypomagnesemia, and the risk may be increased during concomitant use of diuretics or other agents that…2 documented mechanisms | 3 sources — open the full entry |
| Cisplatin | Moderate | Synergy | Chronic use of proton pump inhibitors (PPIs) may induce hypomagnesemia, and the risk may be increased during concomitant use of diuretics or other agents that… | 3 sources — open the full entry |
| Clobetasol Propionate + Neomycin Sulphate + Nystatin | Moderate | Synergy · Unknown | Chronic use of proton pump inhibitors (PPIs) may induce hypomagnesemia, and the risk may be increased during concomitant use of diuretics or other agents that…3 documented mechanisms | 3 sources — open the full entry |
| Cyclosporine (Oral) | Moderate | Synergy | Chronic use of proton pump inhibitors (PPIs) may induce hypomagnesemia, and the risk may be increased during concomitant use of diuretics or other agents that… | 3 sources — open the full entry |
| Dabigatran Etexilate Mesylate | Moderate | Synergy | Patients with gastrointestinal conditions may have an increased risk of gastrointestinal bleeding during concomitant treatment with dabigatran etexilate and… | 4 sources — open the full entry |
| Deferasirox | Moderate | Metabolism | Coadministration with deferasirox may decrease the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism may involve… | 3 sources — open the full entry |
| Dexamethasone + Neomycin + Glacial Acetic Acid | Moderate | Synergy · Unknown | Chronic use of proton pump inhibitors (PPIs) may induce hypomagnesemia, and the risk may be increased during concomitant use of diuretics or other agents that…2 documented mechanisms | 3 sources — open the full entry |
| Dexamethasone + Neomycin Sulphate + Polymyxin B Sulphate | Moderate | Synergy · Unknown | Chronic use of proton pump inhibitors (PPIs) may induce hypomagnesemia, and the risk may be increased during concomitant use of diuretics or other agents that…2 documented mechanisms | 3 sources — open the full entry |
| Dexamethasone + Tobramycin | Moderate | Synergy · Unknown | Chronic use of proton pump inhibitors (PPIs) may induce hypomagnesemia, and the risk may be increased during concomitant use of diuretics or other agents that…2 documented mechanisms | 3 sources — open the full entry |
| Digoxin | Moderate | Absorption | Proton pump inhibitors may increase the bioavailability of digoxin. The mechanism may involve a pH-dependent increase in gastrointestinal absorption of digoxin… | 13 sources — open the full entry |
Conditions
Conditions in which Rabeprazole Sodium needs care, as documented in this source.
Clostridium Infections
MajorPublished observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients. This diagnosis should be considered for diarrhea that does not improve. It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated. Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents. Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C. difficile. C. difficile produces toxins A and B, which contribute to the development of CDAD. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated.
8 sources
- "Product Information. PriLOSEC (omeprazole)." Merck & Co., Inc (2022):
- "Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc (2001):
- "Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals (2001):
- "Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories (2001):
- "Product Information. Protonix IV (pantoprazole)." Wyeth-Ayerst Laboratories
- "Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America (2009):
- "Product Information. NexIUM I.V. (esomeprazole)." Astra-Zeneca Pharmaceuticals (2014):
- "Product Information. Esomeprazole Strontium (esomeprazole)." Amneal Pharmaceuticals (2014):
Fractures, Bone
ModerateVarious published observational studies have reported that PPI therapy may be associated with an increased risk for osteoporosis related fractures of the hip, wrist or spine. The risk was increased in patients who received high doses (multiple daily doses), and long term treatment (a year or longer). Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated. Caution should be used in patients at risk for osteoporosis related fractures and should be managed according to established treatment guidelines.
6 sources
- "Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc (2001):
- "Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals (2001):
- "Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories (2001):
- "Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals (2001):
- "Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc (2003):
- "Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America (2009):
Hypomagnesemia 1, Intestinal
ModerateSymptomatic and asymptomatic hypomagnesemia has been reported rarely in patients treated with PPIs for at least 3 months, in most cases after a year of therapy. Serious adverse events can include tetany, seizures, and arrhythmias. Caution should be used in patients prone to magnesium imbalances such as patients taking other medications that can cause hypomagnesemia (e.g., diuretics). Regular monitoring is recommended.
6 sources
- "Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc (2001):
- "Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals (2001):
- "Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories (2001):
- "Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals (2001):
- "Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc (2003):
- "Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America (2009):
Liver Diseases
ModerateRabeprazole is primarily metabolized by the liver. Although the drug is generally well-tolerated, therapy with rabeprazole should be administered cautiously in patients with severe liver disease because of the lack of clinical data concerning its use in such patients. Dosage adjustments are not necessary in patients with mild to moderate hepatic impairment.
3 sources
- Hoyumpa AM, Trevino-Alanis H, Grimes I, Humphries TJ "Rabeprazole: pharmacokinetics in patients with stable, compensated cirrhosis." Clin Ther 21 (1999): 691-701
- Prakash A, Faulds D "Rabeprazole." Drugs 55 (1998): 261-7;disc. 268
- "Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals (2001):
Therapeutic duplication
Drug classes that overlap with Rabeprazole Sodium, so taking both doubles up the same effect. This source publishes no per-row citations for duplication.
acid suppressant agents
The recommended maximum number of medicines in the 'acid suppressant agents' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'acid suppressant agents' category.
Example product in the source data (US market): Esomeprazole/naproxen
acid suppressant agents
The recommended maximum number of medicines in the 'acid suppressant agents' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'acid suppressant agents' category.
Example product in the source data (US market): Aspirin/omeprazole